CGTX
Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Aug 7, 2026, 00:13 UTC
Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.
Source:Jun 24, 2026, 11:49 UTC
Cognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).
Source: